State management of geothermal energy in Hawaii

"Unsolicited research proposal submitted to the National Science Foundation""This proposal is for a State of Hawaii research project for defining the role of State government in the utilization of geothermal energy. The proposed project will conduct a systematic review of the existing and potential functions of State and County government with the aim of developing a methodology for, and undertaking an assessment of, the management options open to the State of Hawaii. The process itself would then be applicable in assessing the State's management options over other natural energy resources such as wind, sun and ocean thermal differentials. The University of Hawaii is presently engaged in a major geothermal energy research project with joint National Science Foundation, State of Hawaii and County of Hawaii support directed toward the utilization of the State's geothermal resources. The proposed State project will complement the University project and explore the processes and actions required to accelerate the transition from University research results to practical applications of geothermal energy to meet the needs of Hawaii. It will explore the public policy implications and consequences of the introduction of geothermal and other new sources of energy in Hawaii. The project also will serve as a focal point for geothermal energy information dissemination and feedback among the State, County and Federal agencies.

A low-speed generator for energy conversion from marine currents-experimental validation of simulations

Abstract: A low-speed permanent magnet (PM) cable wound generator for electrical energy conversion from marine or tidal currents has been designed and constructed. A key feature of this variable speed direct drive generator is its capability to efficiently generate electricity from tidal currents with very low velocities, in the order of 1 m/s. In arriving at an appropriate design for the generator typical characteristics of tidal currents were considered. Using these characteristics as input, and accounting for the electromagnetic losses, detailed computer simulations using a finite-element method software were carried out to come up with the final design. Various parameters that can influence the generator design are presented. An experimental set-up has been constructed based on the above-mentioned design in order to study the electrical and mechanical performance of the generator through a variety of experiments. The power input for this set-up is a variable speed motor, capable of operating the generator at rotational speeds of 0-16 r/min, representing tidal currents with very low velocities. The generator presented in this paper may be beneficial for a better understanding of an appropriate design and layout of tidal energy conversion systems

Laboratory Measurements of Fe XXIV Line Emission: 3→2 Transitions Near Excitation Threshold

Using the Electron Beam Ion Trap facility at Lawrence Livermore National Laboratory, we have measured relative cross sections for Fe XXIV line emission at electron energies between 0.7 and 3.0 keV. The measurements include line formation by direct electron impact excitation (DE), radiative cascades, resonant excitation (RE), and dielectronic recombination (DR) satellites with captured electrons in n≥5 levels. Good agreement with R-matrix and distorted wave calculations is found. In collisionally ionized plasmas, at temperatures near where the ion abundance peaks (kTe~1.7 keV), the RE contributions are found to be ≲5% of the line emission, while the DR satellites contribute ≲10%. While good agreement with state-of-the-art atomic physics calculations is found, there is less good agreement with existing spectral synthesis codes in common astrophysical use. For the Fe XXIV 3p3/2 → 2s1/2, 3p1/2 → 2s1/2, and 3d5/2 → 2p3/2 transitions, the synthesis code MEKAL underestimates the emissivity in coronal equilibrium by ~20% at temperatures near where the ion abundance peaks. In situations where the ionization balance is not solely determined by the electron temperature, RE and DR satellites may contribute a considerable fraction of the line emission

Emerging drugs for the treatment of vitiligo

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments. Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant mechanisms and repigmenting mechanisms. Topical immunosuppressants may be an alternative to steroids in localized vitiligo. Newer repigmenting agents like basic fibroblast growth factors, afamelanotide have been included and a special emphasis is laid on the upcoming targeted immunotherapy. Expert opinion: The treatment of vitiligo needs to be multimodal with emphasis on targeting different limbs of the pathogenesis. Topical and oral JAK inhibitors are the most promising new class of drugs currently available for treating vitiligo and acts best in conjunction with NB-UVB

Light-based devices for the treatment of facial erythema and telangiectasia

Facial erythema is one of the most common outpatient complaints in dermatology. There are various causes of facial erythema and several devices are available for its treatment. Pulsed dye laser (PDL) and intense pulsed light (IPL) are the two common light devices used for these conditions. In this review, we evaluated the literature to assess efficacy of IPL versus PDL in facial erythema and telangiectasia. We searched published articles including clinical trials or reviews articles, case series, and case reports. Electronic databases (MEDLINE and PubMed) were searched to retrieve the articles. Reference lists of selected articles were also considered for the review. Articles published in English language until June 2021 were considered for this review

The price of tumor control

Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimumab-induced AEs have lead to a reduction of morbidity, e.g. due to bowel perforations. However, the spectrum of less common AEs is expanding as ipilimumab is increasingly applied. Stringent recognition and management of AEs will reduce drug-induced morbidity and costs, and thus, positively impact the cost-benefit ratio of the drug. To facilitate timely identification and adequate management data on rare AEs were analyzed at 19 skin cancer centers. Patient files (n = 752) were screened for rare ipilimumab-associated AEs. A total of 120 AEs, some of which were life-threatening or even fatal, were reported and summarized by organ system describing the most instructive cases in detail. Previously unreported AEs like drug rash with eosinophilia and systemic symptoms (DRESS), granulomatous inflammation of the central nervous system, and aseptic meningitis, were documented. Obstacles included patientś delay in reporting symptoms and the differentiation of steroid-induced from ipilimumab-induced AEs under steroid treatment. Importantly, response rate was high in this patient population with tumor regression in 30.9% and a tumor control rate of 61.8% in stage IV melanoma patients despite the fact that some patients received only two of four recommended ipilimumab infusions. This suggests that ipilimumab-induced antitumor responses can have an early onset and that severe autoimmune reactions may reflect overtreatment. The wide spectrum of ipilimumab-induced AEs demands doctor and patient awareness to reduce morbidity and treatment costs and true ipilimumab success is dictated by both objective tumor responses and controlling severe side effects

Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications

Stem cell factor (SCF), the ligand for c-Kit, is known to regulate developmental and functional processes of haematopoietic stem cells, mast cells and melanocytes. Two different splice variants form predominantly soluble (sSCF or SCF-1) and in addition some membrane-bound SCF (mSCF or SCF-2). In order to explore the prognostic significance of these molecules in melanoma, total SCF, SCF splice variants and c-Kit expression were studied in normal skin melanocytes and in 11 different melanoma cell lines, using reverse transcription polymerase chain reaction, immunocytochemistry and enzyme-linked immunosorbent assay. Nine of the 11 melanoma cell lines expressed SCF-1 mRNA, only two of them SCF-2, and these two also SCF-1. Coexpression of both SCF-1 and c-Kit was noted in five cell lines, and only one cell line as well as normal melanocytes expressed both SCF-1 and SCF-2 as well as c-Kit. Corresponding results were obtained on immunocytochemical staining. Of three exemplary melanoma cell lines studied, two expressing SCF mRNA also released SCF spontaneously and on stimulation, whereas the line lacking SCF and c-kit mRNA (SK-Mel-23) failed to do so. These data demonstrate thus that melanoma cell lines, particularly those known to metastasize in vivo, lose the ability to express SCF-2 mRNA, suggesting that this molecule may serve, next to c-Kit, as a prognostic marker for malignant melanoma. © 2000 Cancer Research Campaig

Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis

Improving access to HIV testing is a key priority in scaling up HIV treatment and prevention services. Home-based voluntary counselling and testing (HBT) as an approach to delivering wide-scale HIV testing is explored here

FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells

Receptor Tyrosine Kinases (RTKs) and Focal Adhesion Kinase (FAK) regulate multiple signalling pathways, including mitogen-activated protein (MAP) kinase pathway. FAK interacts with several RTKs but little is known about how FAK regulates their downstream signalling. Here we investigated how FAK regulates signalling resulting from the overexpression of the RTKs RET and EGFR. FAK suppressed RTKs signalling in Drosophila melanogaster epithelia by impairing MAPK pathway. This regulation was also observed in MDA-MB-231 human breast cancer cells, suggesting it is a conserved phenomenon in humans. Mechanistically, FAK reduced receptor recycling into the plasma membrane, which resulted in lower MAPK activation. Conversely, increasing the membrane pool of the receptor increased MAPK pathway signalling. FAK is widely considered as a therapeutic target in cancer biology; however, it also has tumour suppressor properties in some contexts. Therefore, the FAK-mediated negative regulation of RTK/MAPK signalling described here may have potential implications in the designing of therapy strategies for RTK-driven tumours